Tamibarotene Plus Azacitidine Fails to Improve CR Rates in High-Risk, RARA+ MDS
SELECT-MDS-1 will be discontinued after failing to meet its primary end point of improved CR rates with tamibarotene/azacitidine in high-risk, RARA+ MDS.
Related Articles
Episode 19 | How to Write a Strong Commercialization Plan – Part 1.
In part one of the three-part series on writing a strong commercialization plan, NCI SBIR Program Director William Bozza invites NCI SBIR-funded biotech innovators, Sid…
Biosimilar SCT510 Has Similar Efficacy and Safety as Bevacizumab in NSCLC
Phase 3 data revealed similar safety and efficacy outcomes with SCT510 and bevacizumab.
NanO2 Plus Radiation/Temozolomide Is Under Exploration in Newly Diagnosed Glioblastoma
Early safety findings from the phase 2b RESTORE study (NCT03862430) of NanO2 plus radiation and temozolomide in newly diagnosed glioblastoma were shared.
What is radiation fibrosis? 5 things to know
Radiation fibrosis is a late side effect of radiation treatment. Here, breast radiation oncologist Chelain Goodman, M.D., Ph.D., describes symptoms of radiation fibrosis and strategies…
A SEER Registry-Based Analysis of Pediatric Colorectal Adenocarcinomas
This cohort study analyzes the characteristics of colorectal cancer in pediatric patients using Surveillance, Epidemiology, and End Results (SEER) registry data.
IBI354 Shows Efficacy and Safety in HER2+ and HER2-Low Advanced Breast Cancer
IBI354 favorable safety and efficacy in patients with advanced HER2-positive and HER2-low breast cancer.
Developing a functional precision medicine assay to predict pathological complete response in patients with triple-negative breast cancer: Interim results from the PEAR-TNBC Trial
Introduction: More than 150,000 women die worldwide every year of Triple-Negative Breast Cancer (TNBC). There are a range of treatment options, but no good way…
TREAT ctDNA: early elacestrant intervention for ER+/HER2- breast cancer
Michail Ignatiadis, MD, PhD, Jules Bordet Institute, Brussels, Belgium, comments on the TREAT ctDNA trial (NCT05512364) of elacestrant versus standard endocrine therapy in patients with…
FDA Receives New BLA for Dato-DXd in Pretreated EGFR+ Advanced NSCLC
AstraZeneca has filed a new BLA for Dato-DXd in pretreated, EGFR-mutated advanced non–small cell lung cancer.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.